By Marie Rosenthal
The FDA approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII [FVIII] deficiency) with FVIII inhibitors.
Emicizumab-kxwh is the first new FDA-approved medicine in nearly 20 years to treat hemophilia A with inhibitors. The new treatment is the only option that can be self-administered once-weekly subcutaneously.